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Abstract
Background: N-methyl-D-aspartate receptors (NMDAR) act as tumor suppressors of digestive malignancies. The
expression and genetic methylation patterns of NMDAR2B in non-small cell lung cancer (NSCLC) are unknown.
Methods: The relationship between gene methylation and expression of NMDAR2B was analyzed in NSCLC cell
lines (N = 9) and clinical tissues (N = 216). The cell lines were studied using RT-PCR and 5-aza-2’-deoxycytidine
treatment, while the clinical tissues were examined by methylation specific real-time quantitative PCR and
immunohistochemistry. Retrospective investigation of patient records was used to determine the clinical
significance of NMDAR2B methylation.
Results: NMDAR2B was silenced in five of the nine cell lines; 5-aza-2’-deoxycytidine treatment restored expression,
and was inversely correlated with methylation. Aberrant methylation of NMDAR2B, detected in 61% (131/216) of
clinical NSCLC tissues, was inversely correlated with the status of protein expression in 20 randomly examined
tumors. Aberrant methylation was not associated with clinical factors such as gender, age, histological type, or
TNM stage. However, aberrant methylation was an independent prognostic factor in squamous cell carcinoma
cases.
Conclusions: Aberrant methylation of the NMDAR2B gene is a common event in NSCLC. The prognosis was
significantly better for cases of squamous cell carcinoma in which NMDAR2B was methylated. It may have different
roles in different histological types.
Background
Lung cancer is the leading cause of cancer-related death
in Japan as well as in other countries. Although surgical
techniques and perioperative managements have pro-
gressed, the prognosis of patients with non-small cell
lung cancer (NSCLC) remains poor. Various factors are
linked to the development of NSCLC, such as smoking
tobacco, which is the major risk factor for development
of the disease. In addition to identifying the genetic
alterations associated with development or progression
of NSCLC, other promising avenues of research include
finding new molecular therapeutic targets, as that may
help improve the survival of patients with this type of
cancer.
N-methyl-D-aspartate receptors (NMDAR) are gluta-
mate receptors and constitute the predominant excita-
tory neurotransmitter receptors in the mammalian brain
[1]. NMDAR subunits are also expressed in skeletal
muscle, heart muscle, the pancreas [2,3], and suprabasal
keratinocytes [4]. NMDARs are heteromeric ligand-
gated ion channels that interact with multiple intracellu-
lar proteins through different subunits. Among the
essential NMDARs (type 2A, type 2B, and type 1),
NMDAR2A has the greatest structural and functional
similarity to NMDAR2B [5]. The NMDAR2A coding
sequence shows 78% homology to human NMDAR2B
but no significant homology with the human NMDAR1
subunit that is essential for NMDAR function.
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documented for a number of processes. For example,
NMDAR activation inhibits the outgrowth of keratino-
cytes necessary for some epithelialization processes.
Furthermore, gene expression profiling of human pri-
mary glioblastoma multiforme has shown that NMDARs
are downregulated in brain tumor samples [4,6].
NMDAR2B is methylated in primary human esophagus
squamous cell carcinoma (ESCC) tissues and has exhib-
ited tumor-suppressive activity in ESCC cell lines [7].
The status of NMDAR2B in NSCLC is unknown.
The present expression and methylation study found
that NMDAR2B is frequently methylated in NSCLC and
that methylation status is associated with some clinical
features of NSCLC.
Methods
Cell lines and patients
Nine NSCLC cell lines (HCC193, HCC366, HCC515,
HCC1171, NCI-H1395, NCI-H1770, NCI-H1993, NCI-
H2126, and NCI-H2882) were examined in this study.
These cell lines were established and kindly provided by
Dr. Adi Gazdar of the University of Texas Southwestern
Medical Center. Cell cultures were grown in RPMI-1640
medium (Life Technologies, Inc., Rockville, MD, USA)
supplemented with 5% CO2 at 37°C. Normal bronchial
epithelial cells (NHBECs) were cultured as reported pre-
viously [8] and normal trachea RNA was obtained from
Clontech (Palo Alto, CA, USA).
Surgically resected tumor samples and 120 non-malig-
nant lung tissues were obtained from 216 unselected
NSCLC patients who had not received any treatment
prior to resection at the Chiba University Hospital,
Chiba, Japan, from 1995 to 2000. NSCLC include adeno-
carcinoma (N = 116), squamous cell carcinoma (N =
76), large cell carcinoma (N = 12), and adeno-squamous
cell carcinoma (N = 2). This study was approved by the
Institutional Review Board, and written informed con-
sent was obtained from each participant. All patients
received curative intent surgery. Resected samples were
immediately frozen and stored at -80°C until used.
Methylation status was determined for each patient
sample, and 20 of the 216 cases were randomly selected
for immunohistochemical examination to compare
expression and methylation in primary samples.
RNA preparation and Reverse Transcriptase-PCR
RNA was extracted using Trizol (Invitrogen, Carlsbad,
CA, USA) and reverse transcribed with SuperScript II
reverse transcriptase (Invitrogen). GAPDH expression
was used as an internal control to confirm the success
of the reverse transcription reaction. The primer
sequences used for reverse transcription of NMDAR2B
and GAPDH a r es h o w ni nT a b l e1 .P C Rp r o d u c t sw e r e
analyzed on 2% agarose gels stained with ethidium bro-
mide. NHBEC and normal trachea were used as normal
controls for reverse transcriptase-PCR (RT-PCR).
Treatment of tumor cell lines with 5-aza-2’-deoxycytidine
Five tumor cell lines with negative gene expression were
incubated in culture medium with 1 μMo ft h e
demethylating agent 5-aza-2’-deoxycytidine (Sigma-
Aldrich, St. Louis, MO, USA) for six days, with medium
changes on days one, three, and five. Cells were har-
vested and RNA was extracted on day six.
DNA preparation and real-time quantitative PCR
Genomic DNA was obtained from lung cancer cell lines,
cultured nonmalignant cells, primary tumors and adja-
cent nonmalignant tissues after overnight digestion with
sodium dodecyl sulfate and Proteinase K (Life Technolo-
gies, Inc.) at 37°C, followed by standard phenol chloro-
form (1:1) extraction and ethanol precipitation.
DNA was treated with sodium bisulfite as described
previously [9]. DNA methylation patterns in the CpG
island of the gene were determined using methylation
specific real-time quantitative PCR (Taqman-MSP) [7].
All oligonucleotide primer pairs were purchased from
Table 1 Primer and probe sequences
Primer Assay Sequence
NMDAR2B RT-PCR 5’-GCCTGAGCGACAAAAAGTTC-3’ (forward)
NMDAR2B RT-PCR 5’-CATCTCCCCATCTCCAAAGA-3’ (reverse)
GAPDH RT-PCR 5’-CACTGGCGTCTTCACCACCATG-3’ (forward)
GAPDH RT-PCR 5’-GCTTCACCACCTTCTTGATGTCA-3’ (reverse)
NMDAR2B TAQF Taqman-MSP 5’-GAGTATGGTTATTTTTAAAGCG-3’
NMDAR2B TAQR Taqman-MSP 5’-TTAAAACGAATTAATATCTTTTTCG-3’
NMDAR2B probe Taqman-MSP 6FAM5’-ATTCGCGTGTTTTTCGGAGGGTGA-3’ TAMRA
b-actin TAQF Taqman-MSP 5’-TGGTGATGGAGGAGGTTTAGTAGTAAGT-3’
b-actin TAQR Taqman-MSP 5’-AACCAATAAAACCTACTCCTCCCTTAA-3’
b-actin probe Taqman-MSP 6FAM5’-ACCACCACCCAACACACAATAACAAACACA-3’ TAMRA
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VWR (West Chester, PA, USA). Taqman primer and
probe sequences for NMDAR2B and b-actin are listed
in Table 1. Serial dilutions of human leukocyte genomic
DNA, which was methylated in vitro, were used to con-
struct a calibration curve (Figure 1) (Thermal Cycler
Dice
® Real Time System TP 800); all reactions were
performed in duplicate. The methylation ratio was
defined as the quantity of fluorescence intensity derived
from NMDAR2B promoter amplification divided by
fluorescence intensity from b-actin amplification and
multiplied by 100 [Taqman methylation value (TaqMeth
V)]. Cut off value was defined as 1.0, based on previous
reports [7].
Immunohistochemistry (IHC)
Four micron sections were used for the tissue arrays.
Tissue arrays were deparaffinized in xylene, rehydrated
in graded alcohol, and transferred to PBS. Thereafter,
antigen retrieval was carried out via a microwave in 0.01
M citrate buffer, pH 6.0. Endogenous peroxidase activity
was blocked by incubating sections in hydrogen perox-
ide (0.3%, v/v) for 15 min. Non-specific binding was
blocked with 1% (w/v) BSA in PBS for one hr followed
by incubation with anti-NMDAR2B polyclonal antibody
(1:100) (Chemicon, Temecula, CA, USA) for 16 hr at 4°
C. The primary antibody was detected using biotinylated
secondary antibody and peroxidase-labeled streptavidin
complex using the Dako LSAB Plus Kit (Dako, Glostrup,
Denmark). Color was developed using the chromogen,
diaminobenzidine (DAB). Finally, the slides were
counter stained with Mayer’s hematoxylin and mounted
with D.P.X. Parallel sections in which the primary anti-
body was replaced by nonimmune rabbit IgG of the
s a m ei s o t y p ew e r ee x a m i n e dt o ensure specificity and
exclude cross reactivity between the antibodies and con-
jugates used (negative control).
The staining intensity of NMDAR2B expression was
graded semi-quantitatively into none, weak, moderate,
and strong. Overexpression of NMDAR2B was consid-
ered positive if > 30% of tumor cells were moderately
or strongly stained. Slides were blindly evaluated at
three different times and the average levels were used
by two pathologists (H.T. and Y.M.) for statistical ana-
lyses. IHC photoimaging was done by Carl Zeiss
MicroImaging GmbH and a digital camera (Canon
Power Shot A640).
Statistical Analysis
Fisher’s exact tests were used to assess the association
between categorical variables. Overall survival curves
were calculated with the Kaplan-Meier method and
were compared using the log-rank test. The Cox pro-
portional hazards regression model was used for multi-
variate analysis. Statistical significance was defined as P
values less than 0.05.
Results
Expression and methylation analysis in NSCLC cell lines
The gene expression levels of NMDAR2B in NSCLC cell
lines were assessed by RT-PCR (Figure 2). A comparison
between tumor cell lines and NHBEC and trachea cells
Figure 1 Calibration curve. Serial dilutions of human leukocyte genomic DNA, which was methylated in vitro, were used to construct a
calibration curve.
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Page 3 of 8showed that five out of nine cell lines had lost
NMDAR2B expression (Table 2). The non-expressing
cell lines were treated with 5-aza-2’-deoxycytidine (5-
Aza-CdR) to confirm that aberrant methylation was
responsible for silencing NMDAR2B expression.
NMDAR2B expression was upregulated by 5-Aza-CdR
in five out of five lines (Figure 2, Table 2). Thus, aber-
rant methylation was found in five out of nine NSCLC
cell lines and was inversely correlated with NMDAR2B
expression (Table 2).
Aberrant methylation of NMDAR2B in clinical NSCLC
tissues
NMDAR2B methylation in primary tumors and non-
malignant tissues was analyzed by Taqman MSP (Figure
3). Of 216 NSCLCs, 131 (61%) were methylated, while 5
(4%) of 120 corresponding non-malignant lung tissues
were methylated, indicating that NMDAR2B methylation
was a tumor-specific event (P < 0.0001).
The relationship between methylation and clinical fea-
tures was examined. No significant associations among
gender, age, smoking, histological type, or stage were
observed (Table 3). In terms of survival, the presence of
NMDAR2B methylation was significantly associated with
a better prognosis in squamous cell carcinoma cases (P
= 0.002), but not in adenocarcinoma cases (Figure 4).
Cox proportional hazard regression analysis determined
that NMDAR2B methylation is a prognostic factor inde-
pendent of TNM staging (Table 4). Prognosis was signif-
icantly better for cases of squamous cell carcinoma in
which NMDAR2B was methylated.
Expression of NMDAR2B protein in primary tumors
The typical immunostaining pattern for NMDAR2B in
NSCLC is shown in Figure 5. NMDAR2B was expressed
in bronchial epithelial cells. Using the criteria described
in the Methods section, low NMDAR2B expression was
found in 11 of 20 (55%) tumors, while moderate to
NMDAR2B
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Figure 2 Expression and methylation of NMDAR2B in NSCLCs
cell lines. Representative examples of reverse transcriptase-
polymerase chain reaction results for N-methyl-D-aspartate receptor
type 2B (NMDAR2B) expression in lung cancer cell lines (A), and the
effect of 5-aza-2’-deoxycytidine on NMDAR2B-negative cell lines (B).
Treatment with 5-Aza-CdR restored the expression of NMDAR2B in
four cell lines. Expression of the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was run as a control for RNA
integrity. M indicates size marker; NC, negative control (water blank);
-, before 5-Aza-CdR treatment; +, after 5-Aza-CdR treatment.
Table 2 Expression and aberrant methylation profiles of
NMDAR2B in NSCLC cell lines
Taqman-MSP RT-PCR 5-Aza
HCC193 - + ND*
HCC366 + - +
HCC515 + - +
HCC1171 + - +
NCI-H1395 - + ND
NCI-H1770 - + ND
NCI-H1993 + - +
NCI-H2126 + - +
NCI-H2882 - + ND
* Not done
0.1*
1
10
100
1000
Normal
( 5/120)
Cell line
(5/9)
Tumor
(131/216)
Figure 3 Quantitative analysis of NMDAR2B gene expression in
NSCLCs. Taqman-MSP analysis with a probe targeted to the CPG
island of NMDAR2B was performed using 120 non-malignant lung
tissues, 216 NSCLC samples, and nine cell lines. The cut-off value
was defined as 1.0 based on previous reports [7]; five of 120
nonmalignant lung tissue samples were negative by this cut-off
value.
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eight of the 11 cases, there was low expression of
NMDAR2B protein and methylation of NMDAR2B.T h e
remaining nine cases exhibited moderate to strong
expression of NMDAR2B and unmethylated NMDAR2B.
Thus, there was a significant inverse correlation between
the DNA methylation status of NMDAR2Band the level
of protein expression (P = 0.0014).
Discussion
Kim et al. demonstrated down-regulation of NMDAR2B
in esophageal cancer cells through aberrant methylation
[7]. In this study, decreased NMDAR2B expression in
NSCLC cells was associated with aberrant methylation
of the gene. Expression was restored by treating NSCLC
cells with a demethylating agent. Although there are
other possible mechanisms for down-regulation of
NMDAR2B expression, the excellent concordance
between mRNA expression (RT-PCR) and protein
expression (IHC), indicates that down-regulation in
NSCLC occurs primarily through aberrant methylation.
Among novel methylation genes, NMDAR2B was
found to have a high frequency of methylation in pri-
mary ESCC and strong apoptotic activity in ESCC and
gastric cell lines [7,10]. Studies of NMDAR signaling
have been conducted and the role of NMDAR activity
in apoptosis has been studied intensively in neurons
[11,12], as well as its functional role as a tumor suppres-
sor in human tumors. NMDAR-mediated apoptosis in
human ESCC cell lines was blocked by a specific
NMDAR2B inhibitor, ifenprodil. Surprisingly, BAPRA-
AM, a calcium chelator, was unable to protect cells
against NMDAR2B-induced apoptosis. These results
contrast with previous work in neurons, which indicated
that functional reconstitution of NMDAR-induced apop-
tosis in NSCLC took place through a Ca
2+permeability
independent mechanism [7]. However, the specific
mechanism underlying the growth suppressive effects
and the larger role of NMDAR2B inactivation in the
development of NSCLCs are unknown.
NMDARs constitute the predominant excitatory neu-
rotransmitter receptors in the mammalian brain. There-
fore, the relationship between NMDARs and
neuroendocrine tumors is of interest. Neuroendocrine
tumors in lung cancer exist among small cell lung carci-
nomas (SCLC) and large cell carcinomas. Further study
will be needed to distinguish between NMDAR2B
methylation and neuroendocrine tumors such as SCLC
or large cell carcinoma with neuroendocrine
differentiation.
The significance of NMDAR2B methylation in the
survival of patients with squamous cell carcinoma was
analyzed here by a log-rank test and the Cox propor-
tional hazards regression model. However, due to the
relatively small size of the cohorts in this study (squa-
mous cell carcinoma, N = 76), further validation is
required.
This study shows that NMDAR2B in lung squamous
cell carcinomas may be associated with favorable prog-
noses. There are few reports regarding disease prog-
nosis and gene methylation in lung squamous cell
carcinoma [13-16]. The clinical outcome among
patients with lung squamous cell carcinoma is
improved by Gemcitabine [17], while Pemetrexed is
particularly active in non-squamous NSCLC histology
[18], and it is now clear that chemosensitivity differs
according to histology. Thus, the correlation between
chemosensitivity and squamous cell carcinoma histol-
ogy is now being analyzed, and questions remain. For
example is there a correlation between chemosensitiv-
ity and NMDAR2B methylation? Is NMDAR2B methy-
lation a better predictive marker than tumor histology?
A potential link between NMDAR2B methylation in
squamous cell carcinoma and subtype-specific chemo-
sensitity has to be investigated in future studies.
Further studies are needed to determine the utility of
NMDAR2B methylation and its correlation to chemo-
sensitivity, as a predictive marker in squamous cell car-
cinoma or other cell types.
Conclusions
The results suggest that NMDAR2B methylation is clo-
sely correlated with decreased or absent expression in
Table 3 Methylation status of NMDAR2B and
clinicopathologic factors in clinical NSCLCs
Cases (N = 216) Methylation (N = 131, 61%)
Gender Male (152) 93 (61) *
Female (64) 38 (59)
Age** < 65 (107) 62 (58)
≥ 65 (109) 69 (63)
Smoking Never (64) 36 (56)
Smoker (152) 95 (63)
Histology Adenocarcinoma (126) 68 (54)
Others*** (90) 63 (70)
T factor T1 (135) 81 (60)
T2, 3, 4 (81) 50 (62)
N factor N0 (115) 73 (63)
N1, 2, 3 (101) 58 (57)
Stage I (80) 48 (60)
II, III, IV (136) 83 (61)
*Parentheses in each column indicate percentage of methylation
**Divided by median age
***Others include squamous cell, adenosquamous cell, and large cell
carcinoma
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Figure 4 Survival of NSCLC patients and NMDAR2B gene methylation status. Kaplan-Meier curves of overall survival for 216 patients with
lung cancer (A), 126 patients with adenocarcinoma (B) and 76 patients with squamous cell carcinoma (C). Patients with squamous cell
carcinoma who had aberrantly methylated NMDAR2B genes had a significantly better survival rate compared with patients with unmethylated
receptor genes (P = 0.002).
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Page 6 of 8NSCLC. Because NMDAR2B methylation is common
and specific in NSCLC, it may serve as an important
molecular marker, especially in squamous cell
carcinomas.
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expression), adenocarcinoma (C, D; positive expression) and squamous cell carcinoma (E, F; low expression).
Table 4 Multivariate analyses of prognostic variables in
patients with squamous cell carcinoma of the lung
Variable Multivariate
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